Mozobil Generic Name & Formulations
Plerixafor 20mg/mL; soln for SC inj; preservative-free.
Hematopoietic stem cell mobilizer.
Single-dose vial (1.2mL)—1
In combination with granulocyte colony stimulating factor (G-CSF): To mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.
Mozobil Dosage and Administration
Start after 4 days' treatment with G-CSF. Give by SC inj approx.11hrs before starting apheresis. Repeat up to 4 consecutive days. Base dose on actual body weight. ≤83kg: 20mg fixed dose or 0.24mg/kg once daily; >83kg: 0.24mg/kg once daily. Max 40mg/day. Renal impairment (CrCl≤50mL/min): ≤83kg: 13mg or 0.16mg/kg once daily; >83–<160kg: 0.16mg/kg once daily; max 27mg/day.
Mozobil Boxed Warnings
Not for use in leukemia. May cause mobilization of tumor cells (in combination with G-CSF). Monitor blood and platelet counts. Monitor for splenic enlargement/rupture after administration in combination with G-CSF; evaluate if left upper abdominal pain and/or scapular or shoulder pain occurs. Monitor for signs/symptoms of hypersensitivity during and after administration for at least 30mins. Have anaphylactic treatment readily available. Moderate to severe renal impairment. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 1 week after last dose. Pregnancy: avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after last dose).
May be potentiated by drugs that reduce renal function or compete for active tubular secretion.
Mozobil Adverse Reactions
Diarrhea, nausea, fatigue, inj site reactions, headache, arthralgia, dizziness, vomiting; hypersensitivity reactions (may be serious), tumor cell mobilization, leukocytosis, thrombocytopenia, enlarged spleen, vasovagal reaction may occur.
Mozobil Clinical Trials
Mozobil Patient Counseling